In short
This article discusses a clinical trial investigating the use of Acetylsalicylic Acid Ph. Eur. (commonly known as aspirin) in patients with coronary artery disease who are undergoing coronary artery bypass graft (CABG) surgery. The trial, named ODIN (The One-Month DAPT with Ticagrelor In CABG PatieNts Trial), aims to compare the effects of using ticagrelor in addition to aspirin versus aspirin alone for one month following CABG surgery. The study focuses on the incidence of ischemic events and graft failure within one year after the surgery.
At a glance
- Trial Name
- The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN)
- Trial Category
- Phase 3b
- Medical Condition
- Coronary Artery Disease
- Main Objective
- Compare ticagrelor plus ASA vs ASA alone for 1 month on 1-year ischemic events and graft failure in CABG patients
- Key Inclusion Criteria
- Elective first-time CABG, ≥1 saphenous vein graft, chronic coronary disease
- Key Exclusion Criteria
- Recent ACS, need for dual antiplatelet therapy, inability to undergo CCTA, contraindications to aspirin or ticagrelor
- Primary Endpoint
- Composite of death, stroke, MI, repeat revascularization, and graft failure at 1 year
- Acetylsalicylic Acid Ph. Eur. Details
- Max daily dose: 150 mg, Treatment period: 30 days, Route: Oral use
- Data Sharing
- Pseudonymized participant data will be shared with the sponsor's data coordinating center
What is Acetylsalicylic Acid?
Acetylsalicylic acid, commonly known as Aspirin, is a medication used to treat various conditions, including heart-related issues. In this context, we're discussing a specific form of the drug called "ACETYLSALICYLIC ACID PH. EUR." or Aspirin protect 100 mg. This medication comes as a gastro-resistant tablet, which means it's designed to pass through your stomach and be absorbed in your intestines, potentially reducing stomach irritation.
Medical Condition Treated
The primary medical condition treated with this medication in the context of the study is coronary artery disease. This is a heart condition where the main blood vessels that supply your heart (coronary arteries) become damaged or diseased, usually due to the buildup of fatty deposits called plaque.
Use in CABG Patients
The study focuses on patients undergoing a procedure called Coronary Artery Bypass Graft (CABG) surgery. This is a type of heart surgery used to improve blood flow to the heart in people with severe coronary artery disease. The study aims to compare the effects of using acetylsalicylic acid alone versus using it in combination with another drug called ticagrelor for one month after the surgery.
Dosage and Administration
According to the study information, the maximum daily dose of acetylsalicylic acid is 150 mg, taken orally (by mouth). The maximum total dose amount over the treatment period is 4500 mg, with the treatment lasting up to 30 days. However, always follow your doctor's instructions regarding dosage, as it may vary based on your specific condition.
Potential Benefits
The study aims to determine if this medication can help reduce the occurrence of certain events after CABG surgery. These potential benefits include:
- Reducing the risk of death
- Lowering the chance of stroke
- Decreasing the likelihood of heart attacks (myocardial infarction)
- Reducing the need for repeat revascularization (additional procedures to restore blood flow)
- Improving the success rate of the bypass grafts
Who Can Take This Medication?
Based on the study's inclusion criteria, this medication may be suitable for:
- Patients undergoing elective first-time CABG surgery with at least one saphenous vein graft (a type of blood vessel used in the bypass)
- Individuals with chronic coronary disease
- Patients who can comply with study procedures and follow-up for at least 5 years
Who Should Not Take This Medication?
The study lists several conditions that would exclude a patient from using this medication. These include:
- Recent (within 1 year) acute coronary syndrome or heart attack
- Recent stent placement (PCI) requiring continued dual antiplatelet therapy
- Women who can become pregnant
- Major complications during or after surgery, such as stroke, heart attack, or severe bleeding
- Current or planned use of blood thinners (oral anticoagulation)
- Atrial fibrillation (a type of irregular heartbeat)
- Severe kidney, liver, or respiratory problems
- Cancer or other conditions with a life expectancy less than 5 years
- Known allergies or contraindications to aspirin
It's crucial to discuss your medical history and any current medications with your doctor before starting this or any new treatment.